Alkermes Third-Quarter Revenue Hits $480.1 Million, But Net Income Falls To $16.3 Million
LUMRYZ added $89.9 million in sales, yet Avadel deal costs and new interest expense cut net income from $82.8 million.
Alkermes, which develops and sells medicines for brain and nervous-system diseases, said third-quarter revenue rose to $480.1 million from $394.2 million a year earlier, but net income under standard accounting fell to $16.3 million from $82.8 million. The company reiterated its 2026 forecast in an 8-K filed Tuesday.
LUMRYZ adds sales, deal costs take profit
LUMRYZ, the narcolepsy drug Alkermes gained by buying Avadel, contributed $89.9 million of sales, and about 4,100 patients were on therapy at the end of the quarter. The acquisition closed on Feb. 12, 2026, so the drug had no sales in the year-earlier quarter.
Earnings per diluted share were $0.09, against $0.49 a year earlier. Operating income fell to $36.0 million from $89.1 million, and the company booked $27.6 million of interest expense after having none a year ago. Amortization of acquired intangible assets added $19.7 million of expense.
Adjusted EBITDA, a measure that excludes stock pay and acquisition costs, was $120.1 million, against $121.5 million. Costs tied to the Avadel acquisition were $29.8 million in the quarter.
The other products were mixed. VIVITROL sales rose to $127.6 million from $121.1 million, ARISTADA to $103.9 million from $98.1 million, and LYBALVI slipped to $95.9 million from $98.2 million.
Nine-month loss and the full-year outlook
For the first nine months, Alkermes posted a net loss of $49.7 million, against net income of $192.3 million a year earlier. Revenue for the period was $1,369.1 million, up from $1,091.4 million.
The company reiterated 2026 revenue expectations of $1,730 million to $1,840 million, adjusted EBITDA of $370 million to $410 million and a full-year GAAP net loss of $95 million to $115 million. It expects LUMRYZ net sales of $315 million to $335 million for Feb. 12 through Dec. 31.
Cash, cash equivalents and total investments stood at $787.6 million on Sept. 30, up from $691.6 million at June 30.
Orexin pipeline is the next catalyst
Alkermes markets ARISTADA, LYBALVI, VIVITROL and LUMRYZ in the US, and its main drug in development is alixorexton, for narcolepsy and idiopathic hypersomnia. CEO Blair Jackson said the company expects "several important clinical data readouts over the year ahead" from its orexin programs, citing recent proof-of-concept data in ADHD and a phase 2 study starting in major depressive disorder.
The company plans to file its quarterly report on Form 10-Q in November.
Management's own guide for 2026 still calls for a GAAP net loss, so the third-quarter profit does not change the full-year picture.
Sources
- 8-K Filing — Alkermes plc. (ALKS) — SEC EDGAR
- Exhibit alks-ex99_1.htm — Alkermes plc. 8-K exhibit — SEC EDGAR
- Exhibit alks-ex99_2.htm — Alkermes plc. 8-K exhibit — SEC EDGAR
- Alkermes: Q3 Earnings Snapshot — Associated Press
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates — Yahoo Finance